Sight Sciences, Inc. (SGHT)
8.62
+0.36
(+4.36%)
USD |
NASDAQ |
Oct 20, 16:00
8.635
+0.02
(+0.17%)
After-Hours: 20:00
Sight Sciences Research and Development Expense (TTM) : 10.85M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.85M |
| March 31, 2026 | 12.72M |
| December 31, 2025 | 14.61M |
| September 30, 2025 | 16.46M |
| June 30, 2025 | 17.86M |
| March 31, 2025 | 17.78M |
| December 31, 2024 | 17.99M |
| September 30, 2024 | 17.12M |
| June 30, 2024 | 16.62M |
| March 31, 2024 | 17.52M |
| December 31, 2023 | 17.56M |
| September 30, 2023 | 19.36M |
| Date | Value |
|---|---|
| June 30, 2023 | 21.18M |
| March 31, 2023 | 21.88M |
| December 31, 2022 | 22.86M |
| September 30, 2022 | 21.99M |
| June 30, 2022 | 20.22M |
| March 31, 2022 | 17.84M |
| December 31, 2021 | 15.63M |
| September 30, 2021 | 14.14M |
| June 30, 2021 | 12.02M |
| March 31, 2021 | 9.914M |
| December 31, 2020 | 8.874M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Integra LifeSciences Holdings Corp. | 68.59M |
| Abbott Laboratories | 3.128B |
| AngioDynamics, Inc. | 31.01M |
| Alphatec Holdings, Inc. | 76.69M |
| AtriCure, Inc. | 94.05M |